Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 27Gastrointestinal 25Dermatologic 23Tumor-Agnostic 21Thoracic 21Head & Neck 13Breast 13Sarcoma 8Gynecologic 7Lymphoid 4Other solid neoplasm 2CNS 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Endocrine 1Classical hematology 1

Conditions

Mesothelioma 17Mesothelioma, Malignant 15Solid Tumor 10Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumors 8Melanoma 6Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Advanced Solid Tumor 5Solid Tumors 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Advanced or Metastatic Solid Tumors 3Turcot syndrome 2Stomach Neoplasms 2Neoplasm Metastasis 2Malignant Solid Tumor 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Wilms Tumor 1Vulvar Neoplasms 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

pembrolizumab 7Nivolumab 2Ipilimumab 2Cyclophosphamide 2Cisplatin 2spartalizumab 1regorafenib 1rebastinib 1fludarabine phosphate 1fludarabine 1epacadostat 1enzalutamide 1aldesleukin 1abemaciclib 1Tomography, Optical Coherence 1Talc 1Tablets 1Sirolimus 1Radiofrequency Ablation 1Pemetrexed 1Paclitaxel 1Mitomycin 1Midazolam 1Levoleucovorin 1Leucovorin 1Letrozole 1LY3023414 1Interleukin-2 1Injections 1Immunologic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Nivolumab × Other solid neoplasm × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡